Carlos Tassa

Carlos Tassa has a strong background in the field of genetic medicines and delivery technologies. Currently, they hold the position of Director of Novel Delivery Technologies for Genetic Medicines at Metagenomi. Prior to this, they worked at Verily Life Sciences where they focused on the chemistry of LNPs for RNA delivery as well as target validation and Treg cell therapy. Before joining Verily, Carlos served as a Senior Scientist at Torque Therapeutics and as a Scientist at BIND Therapeutics. Carlos began their career as a Research Scientist at the Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, followed by a Post Doctoral position at the Broad Institute of MIT and Harvard. Throughout their career, Carlos has gained extensive experience in various aspects of the field, making him a valuable asset to any organization.

Carlos Tassa's education history includes a Doctor of Philosophy (PhD) degree in Synthetic Organic Chemistry from Dartmouth College, which they completed in 2005. Prior to this, they obtained a Master of Science (MS) degree in Crystal Engineering from UMass Boston in 1999. Carlos also holds a Bachelor of Applied Science (BASc) degree in Chemistry from UMass Boston, which they obtained in 1996.